

Platelets – it's the special treatment needed

Delordson Kallon

H&I, National Blood Service, NHSBT, England



Will cover...

- Why 'special' platelets
- Role of HLA
- Guidelines for management of Refractory Patients
- Logistics of selected platelet provision



Why 'Special' Platelets - Platelet Refractoriness



Thrombocytopaenia

- Platelet count less than 140 x 10⁹/l
- Haemorrhage occurs 10-30 x 10⁹/l
- Petechiae (pinpoint haemorrhage)
- Ecchymoses (bruising)
- Easy bruising, gum and nose bleeds, haematuria and prolonged menses
- GI blood loss can lead to Iron deficiency and anaemia
- Intracranial Haemorrhage (ICH)





Standard Platelets

Range of platelet products are provided by NBS:

- Pooled donor units derived from platelet rich plasma from whole blood donations (4 donors)
- Single donor platelet units collected by apheresis
 - Over 90,000 adult platelet doses issued in UK each year



Pooled Platelets










Apheresis Platelets





Definition of Platelet Refractoriness

Corrected Count Increment (CCI) of less than between 3,000 – 5,500 per µL per m² per 10¹¹ platelets 1 hour post transfusion.

Platelet Count Increment (/µL) × Body Surface Area (m^2)
Platelets Transfused (× 10^11)

Bishop JF, Matthews JP, Yuen K, McGrath K, Wolf MM, Szer J. The definition of refractoriness to platelet transfusions. Transfus Med 1992: 2: 35-41



Practical Definition

Increase in patient's platelet count of <10 x 10⁹/l between 1 and 24 hours after the transfusion of an adult dose of ABO compatible apheresis platelets on two separate occasions.



Causes of Platelet Refractoriness Non Immune (80%) Immune (20%)

- Bleeding
- Old platelets
- Splenomegaly, hepatomegaly
- DIC
- Infection and its treatment especially amphotericin B
- Fever

- Platelet alloantibodies
 - anti HLA (class I >95%)
 - anti HPA (<5% HPA + HLA, HPA only <1%)
- Other antibodies
 - Autoantibodies
 - Drug-dependent antibodies
 - ABO antibodies
- Immune complexes




Role of Human Leukocyte Antigens (HLA)



Normal role of HLA

- Allow us to recognise "self" from "non-self"
- Provide an alert to the immune system to indicate whether we have an infection or not
- Class I molecules present endogenously derived Ag (viral infection) to CD8+ cytotoxic T cells
- Class II molecules present exogenously derived Ag (bacteria etc) to CD4+ helper T cells







2012

2,013

2,605

1,551

1,260

47

34

176

155

The HLA system is highly polymorphic

		2005	2010
•	HLA-A	349	1,381
•	HLA-B	626	1,927
•	HLA-C	182	960
•	HLA-DRA	3	3
•	HLA-DRB	470	924
•	HLA-DQA1	28	35
•	HLA-DQB1	60	127
•	HLA-DPA1	22	28
•	HLA-DPB1	116	142




Consequences of exposure to foreign HLA

- Exposure to foreign HLA:
 - blood transfusion
 - pregnancy
 - transplantation
- T cell activation; in transplant setting leads to graft rejection and GvHD
- Anti-HLA antibody formation in transfusion setting leading to platelet refractoriness



HLA Antibodies and Platelet Refractoriness






Guidelines for management of Refractory Patients

http://hospital.blood.co.uk/library/pdf/INF139_1_1.pdf




Guidelines



http://hospital.blood.co.uk/library/pdf/INF139_1_1.pdf



Guidelines cont.





Reasons for Increment Data

- To aid in platelet selection (only 30% are fully matched)
 - Identify unacceptable antigens
 - Identify acceptable antigen
- To achieve better clinical response
- To identify if HPA testing is required
- To identify if PAS is required
- To identify if further samples are required for HLA antibody testing
- To not waste a precious resource
- To save money



Case Study

- Patient PT Dob 10/08/1969 (MDS)
- HLA type A1, A3; B7, B8
- Anti HLA Antibodies (Bled 01/01/2011) B13, B27, B38, B39, B44, B45, B64, B64
- No increment data provided but patient reported as responding well to HLA matched platelets in early 2012
- No response to regular requests for new clotted sample



Case Study Cont.

- Oct 2012 hospital call to say patient showing poor response to HLA matched platelets
- New sample bled 13/10/2012
- Testing reveals anti HLA-A2 antibodies
- Look back reveals patient has been receiving platelets from donors with HLA-A2 antigen
- Patient now responding well to HLA matching which avoids HLA-A2 and other newly developed HLA antibodies
- Hospital now sends in regular increment data and samples for testing



Cost 2010/11

• Platelets (1 adult dose) £230.39

Premium

 HLA matched 	£166.71
 CMV-ve 	£7.76
• PAS	£29.43
 Irradiated 	£7.74


• Total £442.03



Logistics of Platelet Provision for Refractory Patients



Number of HLA Selected Platelets Issued





Selected Platelets

- Receive request
- Assess request
- Tissue type and HLA antibody screen patient
- Panels searched to select donor/platelets
- Issue platelets
- Obtain increment data
- Weekly review meetings



Match Grades

- Platelets are matched at the HLA-A and B Loci
- 'A' match = complete match (30%)
- 'B1'- 'B4' match = mismatched for between 1 and 4 HLA antigens (70%)



Match grade 'A' examples

donor A1, A2 ; B8, B44

Patient A1, A2 ; B8, B44

donor* A1, X ; B8, X

Patient A1, A2 ; B8, B44

*homozygous donor



Match grade 'B' match examples

B1 match

donor: A1, A2 ; B8, B27

patient: A1, A68 ; B8, B27

B2 match

donor: A1, A66 ; B7, B27

patient: A1, A68 ; B8, B27



Not off the shelf Products

HLA type of patient

A1,A2 B8,B44 – **597** in 10,000 donors compatible A33,X B58,X - **0** in 10,000 donors are fully matched

- HLA Antibody profile
 - More HLA antibodies = fewer mismatched antigens can be selected
- Additional donation requirements e.g. CMV negativity reduces donor field by approx 50%
- Repertoire of current stock



Emergency On Call Service

- NHSBT provides an emergency out of hours service
- On Call consultant will evaluate clinical urgency with you and call staff in to select HLA matched platelets if indicated



Thank you